Revvity, Inc.

Revvity, Inc. is an American life sciences and diagnostics company headquartered in Waltham, Massachusetts. The company's core business is to provide health science solutions, technologies, expertise, and services to the pharmaceutical and biotechnology industries. Revvity's mission is to expand the boundaries of human potential through science, revolutionizing possibilities in healthcare.

Revvity offers end-to-end workflow solutions spanning from discovery to development, and diagnosis to cure. Its key offerings include translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics. The company's product and service portfolio encompasses reagents, consumables, assays, instruments, and software, serving customers in pharmaceutical and biotech companies, diagnostic labs, academia, and government sectors across more than 160 countries. Notable brands and services include BioLegend, EUROIMMUN, ViaCord, Revvity Signals Software (formerly PerkinElmer Informatics), and Revvity Omics (formerly PerkinElmer Genomics).

Prahlad Singh serves as the President and CEO of Revvity. The company is a component of the S&P 500 index, with approximately 11,000 employees and reported 2025 revenue of $2.9 billion. Recent activities include the declaration of a quarterly dividend of $0.07 per share in April 2026, and the launch of Signals BioDesign, a cloud-based molecular cloning software aimed at advancing biologic research workflows. Revvity also reported strong financial results for the fourth quarter of 2025, exceeding earnings and revenue expectations.